Detection of Mycoplasma Pneumoniae
Clinical Trial Protocol for the Illumigene® Mycoplasma Direct Assay
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Florida
-
Pensacola, Florida, United States, 32513
- Sacred Heart Health System
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- The Children's Mercy Hospital
-
-
Texas
-
Ft. Worth, Texas, United States, 76104-2796
- Cook Children's Healthcare System (CCHCS)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The subject has willingly given written informed consent.
- Specimens provided from subjects with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
- Dual throat swab collected per subject.
Exclusion Criteria:
- Subjects who are unwilling to sign the written informed consent.
- Multiple sets of specimens collected from the same subject.
- Subjects who are unwilling or unable to provide the required number of throat swabs.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Specimen Collection
Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
|
DNA amplification assay
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Qualitative detection of Mycoplasma Pneumoniae to aid in the diagnosis of M. pneumoniae infections.
Time Frame: Up to 14 days
|
Testing of each enrolled subject's samples will be performed within 14 days of collection.
|
Up to 14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Pleural Diseases
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Pneumonia, Bacterial
- Pleurisy
- Mycoplasmatales Infections
- Pneumonia
- Pleuropneumonia
- Mycoplasma Infections
- Pneumonia, Mycoplasma
Other Study ID Numbers
Other Study ID Numbers
- CLIN-DHF-309-004.001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.